RBC Capital Maintains Sector Perform on Intercept Pharma, Lowers Price Target to $14
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Intercept Pharma (NASDAQ:ICPT) and lowers the price target from $17 to $14.
June 15, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intercept Pharma's price target has been lowered from $17 to $14 by RBC Capital, while maintaining a Sector Perform rating.
The lowering of Intercept Pharma's price target by RBC Capital from $17 to $14 indicates a negative outlook for the stock in the short term. The maintained Sector Perform rating suggests that the stock is expected to perform in line with the market, but the reduced price target could lead to downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100